List
The results of your search are listed below. To view the details of a trial or study, click on the "SEE DETAILS" button. Or start a new search.
Searched for: Lymphoma, Large B-Cell, Diffuse. 15 results shown below.
JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Complete title: A Phase 1b Study of JCAR014, Autologous T cells Engineered to Express a CD19-specific Chimeric Antigen Receptor, in Combination with Durvalumab (MEDI4736) for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Principal Investigator: Cameron Turtle, PhD, MBBS
Study Number: 9457
Phase: I
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
Complete title: A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
Principal Investigator: Mazyar Shadman
Study Number: 9738
Phase: I/II
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Complete title: Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients with Hematologic Malignancies using Related, HLA-Haploidentical Donors: A Phase II trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
Principal Investigator: Rachel Salit
Study Number: 2372.00
Phase: II
huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
Complete title: A Two-Stage Phase 1 Open-Label Study of huJCAR014, CD19-targeted Chimeric Antigen Receptor (CAR)-Modified T cells Bearing a Human Binding Domain, in Adult Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Acute Lymphocytic Leukemia
Principal Investigator: Cameron Turtle, PhD, MBBS
Study Number: 9364
Phase: I
Rituximab and Pembrolizumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma
Complete title: Phase II Study of Rituximab Plus Pembrolizumab (MK-3475) in Subjects with Relapsed Follicular and Diffuse Large B-Cell Lymphoma
Principal Investigator: Stephen Smith
Study Number: 9469
Phase: II
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Complete title: A Randomized Phase II Study to Compare the Net Clinical Benefit of Cyclosporine and Sirolimus combined with MMF or Post-Transplant Cyclophosphamide as GVHD Prophylaxis after HLA-Matched or HLA-Mismatched Unrelated G-CSF Mobilized Blood Cell Transplantation using Nonmyeloablative or Reduced Intensity Conditioning for Patients with Hematologic Malignancies: A Multi-Center Trial
Principal Investigator: Masumi Ueda
Study Number: 9816
Phase: II
Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Complete title: A randomized double-blind phase III study of ibrutinib during and following autologous stem cell transplantation versus placebo in patients with relapsed or refractory diffuse large B-cell lymphoma of the activated B-cell subtype
Principal Investigator: Leona Holmberg, MD, PhD
Study Number: A051301
Phase: III
Axicabtagene Ciloleucel Expanded Access Study (ZUMA-9)
Complete title: A Multicenter, Open-Label, Expanded Access Study Of Axicabtagene Ciloleucel For The Treatment Of Subjects With Relapsed/Refractory Large B-Cell Lymphoma
Principal Investigator: David Maloney, MD, PhD
Study Number: 10002
Phase: N/A
Safety Study of SEA-CD40 in Cancer Patients
Complete title: A Phase 1, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult Patients with Advanced Malignancies
Principal Investigator: Andrew Coveler, MD
Study Number: 20150420
Phase: I
Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma (UNITY-NHL)
Complete title: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma
Principal Investigator: Ryan Lynch
Study Number: 20161033
Phase: II/III
PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Complete title: A Phase 1 Dose Escalation and Expanded Cohort Study of PF-06821497 in the Treatment of Adult Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL)
Principal Investigator: Michael Schweizer
Study Number: 20181583
Phase: I
Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL)
Complete title: A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory(R/R) B-cell Non-Hodgkin Lymphoma (NHL)
Principal Investigator: David Maloney, MD, PhD
Study Number: 9734
Phase: I
A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Complete title: An Open-Label, Multicenter, Phase I/IB Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses Of BTCT4465A as a Single Agent and Combined with Atezolizumab in Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
Principal Investigator: Mazyar Shadman
Study Number: 9837
Phase: I
Study of CLR 131 in Relapsed or Refractory Select B-Cell Malignancies
Complete title: An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies
Principal Investigator: Damian Green, MD
Study Number: 9847
Phase: II
Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers
Complete title: A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton's Tyrosine Kinase Inhibitor, SNS-062, in Patients With B-Lymphoid Malignancies
Principal Investigator: Mazyar Shadman
Study Number: RG1004747
Phase: I/II